Approximately 6.5 million American adults ages sixty-five and older are currently living with Alzheimer s disease (AD). Although the progressive neurologic disorder actually begins decades before patients experience any symptom onset– such as difficulty completing tasks, challenges
Plasma phosphorylated tau (P-tau181), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) seem feasible as plasma biomarkers for detecting Alzheimer disease in presymptomatic individuals.
FRIDAY, Jan. 13, 2023 (HealthDay News) Plasma phosphorylated tau (P-tau181), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) seem feasible as plasma biomarkers for detecting Alzheimer disease in presymptomatic individuals, according to a study published online Jan. 11 in Brain. Charlotte Johansson, from Karolinska Institutet in Stockholm, and colleagues explored the timing